Andrew M Evens DO , MBA, MSc

Summary

• I am the Deputy Director for Clinical Services and Chief Physician Officer at the Rutgers Cancer Institute and the Jack and Sheryl Morris Cancer Center, Associate Vice Chancellor for Clinical Innovation and Data Analytics at Rutgers Health, and Oncology Lead for the RWJBH Medical Group and System Director of Medical Oncology for RWJBarnabas Health. I oversee the clinical enterprise to deliver innovative, high-quality, and integrated cancer care across 15 acute care hospitals and associated ambulatory practices throughout New Jersey. I work closely with Rutgers Health and RWJBarnabas Health system executive leadership to advance innovative, efficient, and dynamic healthcare systems.
  
  Clinically, I am an expert in lymphoid malignancies, with research interests in studying novel targeted therapeutic agents, biomarker discovery, predictive modeling, big data, and personalized medicine. My research has been funded continuously by the NIH and the NCI since 2005, which has resulted in 400+ research abstract presentations and 250+ manuscripts in peer-reviewed journals. Additionally, I am the co-founder and co-PI of the NCI-funded international Hodgkin lymphoma consortium known as HoLISTIC (Hodgkin Lymphoma International STudy for Individual Care: www.hodgkinconsortium.com).
  
  I am a re-elected member and the Chair-Elect for the North American Lymphoma Research Foundation Scientific Advisory Board, comprised of 45 world-renowned lymphoma experts. I am a Hodgkin Lymphoma NCI steering committee member and have been an ad hoc member of varied sub-committees for the NIH, NCI, CTEP, and the FDA. I am also the editor-in-chief of the global hematology journal, BJHaem, the vice-chair of the lymphoma committee for ECOG-ACRIN, co-chair of the Big 10 Cancer Research Consortium lymphoma committee, and a recently elected member of the Board of Directors for the American Society of Hematology (ASH) Research Council.

Dr. Evens' Perspective on the Annual Oncology Clinical Practice and Research Sum
Dr. Andrew Evens discusses the evolution of the Annual Oncology Clinical Practice and Research Summit over the years, as well as its regional importance.

Optimizing Quality of Life: Reducing Toxicity in Hodgkin Lymphoma Care - The Pat
Dr. Sam Siegel and Dr. Andy Evens from Rutgers Cancer Institute discuss how to reduce the toxicity of Hodgkin's lymphoma treatments.

Consortium aims to improve outcomes for adolescents, young adults with lymphoma
The Lymphoma Research Foundation formed a multidisciplinary consortium dedicated to advancing and harmonizing treatment for adolescents and young adults.

Rutgers Cancer Institute Unveils Leadership Enhancements for Next Era of Excelle
New Brunswick, N.J., January 30, 2024 - To further support its mission and vision, Rutgers Cancer Institute has enhanced its leadership structure.

What It Takes to Harmonize the World's Hodgkin Lymphoma Data | Blood Cancers Tod
Susan Parsons, MD, MRP; Andrew Evens, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the genesis, journey, and destiny of our global #HoLISTIC consortium.

Development & Evaluation E-HIPI HoLISTIC Consortium Report [ASH 2023]
In an interview, Andrew Evens, DO, an expert in hematology and oncology, discusses a study on predicting survival in early-stage Hodgkin lymphoma.

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compare
A practice-changing presentation/study phase 3 study integrating checkpoint inhibitor immunotherapy into frontline therapy for older Hodgkin lymphoma adults.
Lymphoma in adolescents and young adults: Navigating a path forward together
A SPECIAL ISSUE published in the eJHaem journal includes 7️⃣ mini-reviews from top pediatric & adult oncology clinical & scientific experts across the world.

New Data Informs Treatment of Blood Cancer During Pregnancy
Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival

Investigators Develop Model to Predict Overall Survival in Adults Diagnosed with
New Brunswick, NJ and Boston, MA, December 10, 2022 - Investigators fromRutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Ca

Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens
Andrew M. Evens, DO, MSc, associate director, Clinical Services, Rutgers Cancer Institute of New Jersey, system director, Medical Oncology, oncology lead, Combi

Meet The Professor: Optimizing the Clinical Management of Hodgkin and Non-Hodgki
Andrew M Evens, DO, MSc Introduction DR LOVE: Good afternoon, everyone. This is Neil Love from Research To Practice, and welcome to Meet The Professor. And toda

Lymphoma During Pregnancy
VuMedi is a video education platform for doctors. Over 450,000 doctors use VuMedi to improve patient care and grow their practice.

Current treatment strategies for older and frail patients with HL and future out
Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares some insights into treatment strategies for older and frail patients with Hodgkin lym

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin
Investigators from Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center and leading cancer program along with Tuf

Perspective on the Annual Oncology Clinical Practice and Research Summit
VuMedi is a video education platform for doctors. Over 450,000 doctors use VuMedi to improve patient care and grow their practice.

Andrew M. Evens, DO, MSc @DrAEvens @RutgersCancer #ASH20 #Lymphoma #Cancer #Rese
Andrew M. Evens, DO, MSc from Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey discusses the ASH 2020 abstract - 476 Real Worl

ASH 2019 Interview - Prof Andrew Evens - HoLISTIC Hodgkin Lymphoma International

International Consortium Aims to Enhance Decision-Making in Hodgkin Lymphoma
Harmonization of big data in examining acute and long-term outcomes with contemporary treatment for pediatric and adult patients with Hodgkin lymphoma is yieldi

Protecting your Heart Before, During and After Cancer Treatment
New Brunswick, N.J., July 21, 2021 - Cardiac care is not likely the first thing on a patient's mind when fighting cancer, however, cancer and cardiovascular iss

New Jersey cancer center launches state's 1st home infusion program
Eligible cancer patients will soon be able to get infusion treatments at home through a pilot program from New Brunswick-based Rutgers Cancer Institute of New J

$3.5 Million NIH Grant will Help Harness Worldwide Big Data to Enhance Decision
Newswise - New Brunswick, NJ and Boston, MA, March 15, 2022 - With the aid of a recently awarded $3.5 million, five-year National Cancer Institute grant (R01CA2

Collaborate and Innovate RWJBarnabas Health and Rutgers Cancer Institute of New
CANCER CARE 2018 At the American Society of Hematology Annual Meeting in February, Dr. Andrew Evens presented a study showing the best outcomes to date for cert

Current treatment strategies for older and frail patients with HL and future out
Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares some insights into treatment strategies for older and frail patients with Hodgkin lym

Treating Newly-Diagnosed Hodgkin Lymphoma
Andrew Evens, DO, MSc, FACP, Associate Director for Clinical Services, Rutgers Cancer Institute of New Jersey, Medical Director, RWJBarnabas Health, New Brunswi

Dr Andrew Evens on a New Predictive Model in HL
A new multivariable, clinical prognostic model appeared to predict progression-free survival (PFS) and overall survival (OS) by 5 years in adult patients with u

Dr Andrew Evens on the SWOG S1826 Trial and Changing Landscape of Hodgkin Lympho
Andrew Evens, DO, MBA, MSc, associate director for clinical services at Rutgers Cancer Institute, discussed the ways in which SWOG S1826 trial results will buil

Current treatment strategies for older and frail patients with Hodgkin Lymphoma.
Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares insights into treatment strategies for older & frail patients with Hodgkin lymphoma.
Hodgkin Lymphoma 2022- The ASCO Post
The ASCO Post Roundtable series on updates in Hodgkin lymphoma with Dr. Andrew Evens, Rutgers CINJ; Dr Alison Moskowitz, MSKCC; and Dr Ann LaCasce, Dana Farber.

An insight into the HoLISTIC consortium and value of international collaboration
Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares some insights into emerging international collaborations in Hodgkin lymphoma (HL).

Dr. Andrew Evens Discusses his Research on Lymphoma
Link to Dr. Evens' profile here: https://www.cinj.org/andrew-m-evens-do-mba-msc